Investment Rating - The report maintains an investment rating of "Outperform" with a rating of A [7] Core Insights - The report highlights significant advancements in small nucleic acid drugs for the treatment of hepatitis B, particularly the promising data from the drug AHB-137 presented at the AASLD 2025 conference, indicating its potential as the best small nucleic acid drug for hepatitis B [3][22] Summary by Sections Weekly New Drug Market Review - From November 17 to November 23, 2025, the top five gainers in the new drug sector were: - LaiKai Pharmaceutical (+13.34%) - Beihai Kangcheng (+2.67%) - Jiahe Biotech (+2.19%) - Yongtai Biotech (+1.94%) - Youzhi You (+1.14%) - The top five losers were: - WuXi AppTec (-15.75%) - Adi Pharma (-14.56%) - Mengke Pharma (-14.34%) - Yiming Oncology (-13.40%) - Kain Technology (-13.04%) [1][16] Weekly Focused Investment Targets - The report suggests focusing on several promising targets due to upcoming catalysts, including: 1. Products with high certainty for overseas expansion certified by MNCs: Sanofi, Federated Pharmaceuticals, and Kelun-Botai 2. Products with overseas data catalysts: Betta Pharmaceuticals, Hutchison China MediTech, and Yiming Biotech 3. Potential blockbuster products for overseas licensing by MNCs: Fuhong Hanlin, CSPC Pharmaceutical Group, and Yifang Biotech 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat reduction and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2][20] Weekly New Drug Industry Analysis - The report emphasizes the breakthrough data for small nucleic acid drugs in treating hepatitis B, particularly the two-phase follow-up data for AHB-137, which shows a high potential for becoming the leading small nucleic acid drug in this field [3][22] Weekly New Drug Approval & Acceptance Status - No new drug or new indication approvals were reported this week, but six new drug or new indication applications were accepted [4][24] Weekly New Drug Clinical Application Approval & Acceptance Status - This week, 42 new drug clinical applications were approved, and 44 new drug clinical applications were accepted [5][26] Domestic Market Key Events TOP3 - Key events included: 1. Zean Biopharma's strategic collaboration with GSK to develop up to four "first-in-class" candidates in oncology [11] 2. Innovent Biologics announcing successful Phase III clinical study results for a drug in moderate to severe obesity [11] 3. Fuhong Hanlin's FDA approval for a biosimilar product [11] Overseas Market Key Events TOP3 - Key events included: 1. Merck's presentation of key Phase III trial results at the AHA Scientific Sessions [12] 2. Johnson & Johnson's acquisition of Halda Therapeutics for $3.05 billion [12] 3. The EMA's recommendation for the approval of a gene therapy product [12]

Investment Rating - The report maintains a "Recommended" rating for the industry [1] Core Views - The report highlights a return of inflation trading, with consumer goods showing a positive trend in performance [1][8] - The overall industry size is significant, with a total market capitalization of 18,186 billion and a circulating market capitalization of 16,721.2 billion [1] Summary by Sections Macroeconomic Analysis - Retail sales growth year-on-year is at 2.9%, with a slight recovery in October due to the holiday effect, showing a month-on-month increase of 0.16% [6] - The restaurant sector saw a year-on-year revenue increase of 3.8% in October, while jewelry sales surged by 37.6% [6][7] - Service retail sales grew by 5.3% year-on-year from January to October, indicating a gradual recovery in service consumption [7] Food and Beverage Sector - October inflation data exceeded expectations, with both CPI and PPI showing improvements, suggesting a potential recovery in profitability for the food and beverage sector [8] - Companies like Haidilao and Anjuke are expected to perform well due to improved demand and operational strategies [9][10] Textile and Apparel Sector - The textile manufacturing sector is experiencing stable overseas demand, with major brands like NIKE showing signs of recovery [12] - Recommendations include focusing on leading manufacturers with optimized order structures and production efficiency [12] Tobacco Sector - The report recommends companies like Smoore International and China Tobacco Hong Kong, highlighting their stable growth and market positioning [16] Home Appliances Sector - The report suggests focusing on leading white goods manufacturers like Midea Group, which has shown stable operational performance [17] Retail and E-commerce - The report notes a significant increase in e-commerce sales during the Double Eleven shopping festival, with a total sales growth of 14.2% [24] - Companies like JD.com are expected to maintain robust growth, with a projected non-GAAP net profit of 318 billion for 2025 [25] Pharmaceutical Sector - The report emphasizes the importance of innovation in the pharmaceutical industry, recommending companies like Innovent Biologics and 3SBio for their strong project pipelines [27] Agriculture Sector - The report indicates a rapid reduction in sow production capacity, suggesting a potential increase in pig prices in 2026 [28]

Group 1: Regulatory Changes in Cosmetics Industry - The National Medical Products Administration (NMPA) has released opinions to streamline the registration process for new functional cosmetics, implementing an immediate review system [1] - The new measures encourage international cosmetic products to debut in China without needing overseas sales proof and support product development targeting the elderly [1] - The aim is to address bottlenecks in the cosmetics industry and inject new vitality for high-quality development [1] Group 2: Clinical Approvals in Pharmaceuticals - Heng Rui Medicine announced that its HRS-6209 capsules and HRS-2189 tablets have received clinical trial approval from the NMPA, indicating strong R&D capabilities in innovative drugs [2] - The recent approvals of multiple anti-cancer drugs are expected to boost the company's stock price in the short term [2] Group 3: Strategic Investments in Pharmaceutical Sector - Nanjing Medicine has received approval for Guangzhou Pharmaceutical Group's second-phase fund to acquire 11.04% of its shares, valued at RMB 749 million [3] - This strategic cooperation between Baiyunshan, Nanjing Medicine, and the fund is expected to enhance business collaboration and optimize regional industrial layout [3] Group 4: Stock Performance and Market Sentiment - Renmin Tongtai has reported that its stock price has significantly deviated from its operational performance, indicating potential risks of market overreaction and irrational speculation [4] - The company warns investors to be cautious of the stock's volatility and high valuation risks due to the current market sentiment [4] Group 5: International Market Approvals - Fuhong Hanlin announced that its self-developed biosimilar of Pertuzumab has been approved by the FDA, becoming the first and only biosimilar of its kind in the U.S. market [5] - This approval signifies recognition of the company's products in the international market and is expected to enhance its global influence [5]

Core Insights - In 2024, China approved 48 innovative drugs for market entry, ranking second globally, just behind the United States with 50 approvals. In the first half of this year, the National Medical Products Administration approved 43 innovative drugs, marking a 59% year-on-year increase [1] Policy Guidance - Beijing has implemented a series of pioneering reforms in the pharmaceutical and health sector, including the establishment of green channels for rare disease drug approvals and optimizing clinical trial reviews. These measures aim to create a favorable environment for high-quality industry development [2] - The Beijing Municipal Science and Technology Commission has introduced 32 new measures to support the high-quality development of innovative pharmaceuticals and medical devices [2] - Chengdu has also rolled out specific policies to support the biopharmaceutical industry, focusing on drug and device R&D innovation and enhancing clinical research quality [2] Innovation Ecosystem - Chengdu's Tianfu International Biotech City is a key hub for the biopharmaceutical industry, housing 108 clinical research drugs, including 63 in clinical stages. The "Wutong Plan" launched by Chengdu High-tech Zone offers a comprehensive service list for the pharmaceutical health industry [3] - Jiangsu province has established a robust innovation ecosystem, exemplified by the production of the world's first dual-target weight-loss drug, which was approved in just 16 months [4] Comprehensive Innovation Efforts - Jiangsu has concentrated resources in policy, funding, and talent to strengthen its innovative platforms and tackle key technological challenges in the biopharmaceutical sector [5][6] - The National Biopharmaceutical Technology Innovation Center is focusing on critical technology R&D and public platform construction, with 66 projects already initiated [6] Capital Support - The capital market is increasingly supporting innovative drug development, with Beijing's Changping District establishing a multi-faceted investment framework, including a 200 billion yuan pharmaceutical investment fund [7] - The Zhongguancun Life Science Park in Changping has become a hub for cell and gene therapy, with over 20 companies advancing their products into clinical research [7] - Jiangsu's Shengsheng Biopharmaceutical Co. has committed to significant R&D investments, increasing its budget from 20 billion yuan in the first five years to nearly 80 billion yuan in the subsequent five years [7] Industry Layout - Under the dual support of policies and funding, various regions are accelerating their focus on cutting-edge fields, enhancing both the innovation and industrial chains [8] - The Suzhou Biopharmaceutical Industrial Park has gathered over 620 innovative pharmaceutical companies and more than 35,000 R&D talents, establishing a strong foundation for drug development and high-end medical devices [8]

Core Insights - In 2024, China approved 48 innovative drugs for market entry, ranking second globally, just behind the United States with 50 approvals, marking a significant growth in the innovative drug sector [1] - The approval of innovative drugs has surged, with a 59% year-on-year increase in the first half of the year, reflecting the impact of long-term policy guidance, technological accumulation, and capital cultivation [1] Policy Guidance - Beijing has implemented a series of pioneering reforms in the pharmaceutical and health sector, including the establishment of green channels for urgently needed imported drugs and optimizing clinical trial approvals, creating a favorable environment for high-quality industry development [2] - The city has introduced 32 new measures to support the high-quality development of innovative pharmaceuticals and medical devices, focusing on resource allocation and fostering a quality innovation ecosystem [2] - Chengdu has also launched specific policies to support the biopharmaceutical industry, emphasizing drug and device R&D innovation and enhancing clinical research quality [2] Innovation Ecosystem - Chengdu's Tianfu International Biotech City is a key hub for the biopharmaceutical industry, housing 108 clinical research drugs, including 63 in clinical stages, supported by a comprehensive service plan for the entire lifecycle of the pharmaceutical industry [3] - Jiangsu province has established a robust innovation ecosystem, exemplified by the rapid approval of the innovative drug Ma Shidu Tie, which took only 16 months from application to market [4] Comprehensive Innovation Efforts - Jiangsu is concentrating resources on key areas of biopharmaceuticals, establishing seven national key laboratories and a national technology innovation center to enhance R&D capabilities [5][6] - The National Biopharmaceutical Technology Innovation Center is focusing on critical technology R&D and public platform construction, with 66 projects initiated, including 21 breakthrough technologies [6] Capital Support - The innovative drug development process is capital-intensive and lengthy, prompting Beijing to create a multi-faceted investment model involving government and social capital, with significant funds allocated to support innovative drug companies [7] - The Zhongguancun Life Science Park in Beijing has become a hub for cell and gene therapy, with over 20 companies advancing their products into clinical research stages [7] - Jiangsu's Shengsen Biopharmaceutical Co. has committed to substantial R&D investments, increasing its budget from 2 billion yuan in the first five years to nearly 8 billion yuan in the subsequent five years [7] Industry Development - Under the dual support of policies and funding, various regions are accelerating their focus on cutting-edge fields, with Beijing prioritizing areas like brain-computer interfaces and gene therapy [8] - The Suzhou Biopharmaceutical Industrial Park has become a significant incubator for innovative drug R&D and high-end medical devices, housing over 620 pharmaceutical innovation companies and more than 35,000 R&D talents [8]

Investment Rating - The report maintains an investment rating of "Outperform" [4] Core Insights - The innovative drug sector is experiencing a surge in business development (BD) transactions, with expectations for multiple BD deals to emerge in Q4 2025. As of October 2025, there have been 175 overseas licensing BD transactions in the domestic innovative drug sector, with a total contract value of $104.2 billion and upfront payments reaching $8.1 billion, surpassing the total figures for the entire year of 2024 [2][17][18]. Summary by Sections Weekly New Drug Market Review - From November 10 to November 16, 2025, the top five gainers in the new drug sector were: - Gilead Sciences (+45.40%) - Lai Kai Pharmaceutical (+27.93%) - Jiahe Biopharma (+24.61%) - Zhongsheng Pharmaceutical (+24.46%) - Kaitu Pharmaceutical (+22.81%) - The top five losers were: - Yongtai Biopharma (-7.74%) - Junsheng Tai (-7.43%) - Weixin Biopharma (-1.87%) - Zai Ding Pharmaceutical (-0.93%) - Maibo Pharmaceutical (-0.00%) [1][13][15] Recommended Focus Stocks - The report suggests focusing on several stocks with potential catalysts, including: 1. Products with high overseas sales certainty certified by MNCs: - PD-1 upgraded product: Sanofi - GLP-1 asset: Lianbang Pharmaceutical - ADC asset: Kelun-Botai 2. Potential heavyweights for overseas licensing from MNCs: - PD-1 upgraded product: Kangfang Biopharma - Breakthroughs in autoimmune fields: Yifang Biopharma, China Antibody - Innovative target ADC: Fuhong Hanlin, Shiyao Group 3. Stocks likely to benefit from medical insurance negotiations and commercial insurance innovative drug directories: - Expected beneficiaries from medical insurance directory: Hengrui Medicine, Kangnuo Pharmaceutical, Maiwei Biopharma, Zhixiang Jintai, Haichuang Pharmaceutical - Expected beneficiaries from commercial insurance innovative drug directory: WuXi AppTec, Kexin Pharmaceutical [2][17] New Drug Approval and Acceptance - This week, four new drugs or new indications received approval, and six new drugs or new indications were accepted for review [3][24]. Clinical Application Approval and Acceptance - This week, 43 new drug clinical applications were approved, and 43 new drug clinical applications were accepted [7][27].

近日，A股上市公司三季度财报发布收官，四川179家A股上市公司的"成绩单"披露。记者依据 Wind数据初步统计，2025年前三季度，川股上市公司合计实现营业总收入8231亿元，归母净利润821.5 亿元。川股整体经营成色如何？不同行业的发展又呈现出怎样的差异？记者带着问题梳理了川股三季 报。 营收盈利分化显著 技术突破驱动业绩爆发 在部分传统行业承受经营压力的同时，以通信、军工为代表的新兴产业板块正成为川股增长的"新 引擎"。例如，新易盛的爆发式增长就很引人瞩目。 作为通信模块龙头企业，新易盛前三季度交出了一份亮眼的"成绩单"。财报数据显示，公司前三季 度营收165.05亿元，同比飙升221.70%；净利润63.27亿元，增幅达355.77%，凭借这一业绩表现，新易 盛直接跻身川股盈利榜第四位，成为川股新兴产业中的"领军者"。 华丰科技的业绩表现同样可圈可点。前三季度实现营收16.59亿元，较去年同期增长121.47%；实现 归母净利润2.23亿元，较去年同期实现扭亏为盈，盈利能力显著提升。记者了解到，在全球数字化进程 加速及能源结构转型的驱动下，华丰科技通过技术创新与市场拓展，实现了业绩的突破性增长。 31 ...

Core Viewpoint - The article emphasizes the importance of the innovation-driven pharmaceutical industry in China, highlighting the trend of internationalization and the potential for growth in both innovative drugs and medical devices, while also addressing the challenges posed by domestic demand and healthcare financing [2][3][4]. Group 1: Innovation and Internationalization - The Chinese innovative pharmaceutical industry has transitioned from "importing and imitating" to "innovating and exporting," with significant internationalization evidenced by increasing license-out deals and collaborations [3][5]. - By 2025, Chinese innovative drugs are expected to demonstrate global competitiveness with high-quality clinical data presented at major international conferences [5][9]. - The trend of innovative drugs is supported by improved financing conditions and a favorable regulatory environment, leading to a new cycle for CXO and upstream sectors [3][4]. Group 2: Domestic Demand and Healthcare Financing - Domestic demand has been weak but is gradually improving, with commercial insurance playing a crucial role in alleviating payment conflicts [3][4]. - The healthcare sector is undergoing a normalization phase post-medical corruption investigations, which is expected to ease the impact on the industry by 2025 [3][4]. - The article highlights the need for a multi-layered healthcare financing system, with commercial insurance expected to inject new vitality into the payment landscape [24][25]. Group 3: Investment Strategies - The "barbell strategy" remains applicable in 2026, combining aggressive investments in innovative healthcare technologies with defensive positions in traditional dividend-paying stocks [4][22]. - The article suggests that high-dividend pharmaceutical stocks still have room for valuation recovery, particularly in light of the aging population and the essential nature of healthcare demand [23][24]. - Key investment windows are identified around the release of 2025 annual reports and the end of 2026, as these periods may attract institutional investment due to clearer assessments of dividend sustainability [23][24]. Group 4: Medical Devices and Equipment - The medical device sector is expected to see a recovery, with companies gradually clearing inventory and improving revenue growth [14][18]. - The article notes that the competitive landscape for medical devices is shifting, with high-end products maintaining price stability while lower-end products face price competition [18][19]. - Chinese medical device companies are accelerating their international expansion, with overseas revenue growth outpacing domestic revenue growth [19][20]. Group 5: Future Outlook - The integration of AI in healthcare is anticipated to create new tools and business models, particularly in drug development and clinical diagnostics [20][21]. - The article posits that while rapid growth in new technologies may be challenging in the short term, supportive policies and clear clinical needs will present investment opportunities in the healthcare sector [21][22].

Core Viewpoint - The article discusses the recent surge in IPO applications from biopharmaceutical companies in Hong Kong, highlighting the improved market conditions and the resulting differentiation among industry players in terms of survival and development anxiety [4][5]. Group 1: Market Environment - The recent IPO wave is attributed to a significant improvement in the Hong Kong market environment, driven by rising secondary market stock prices and the Federal Reserve's interest rate cuts, which have redirected funds into emerging markets [4][5]. - Daily trading volume in Hong Kong stocks has surged to several hundred billion HKD, significantly increasing institutional investor interest and providing a financing window for biopharmaceutical companies [5]. Group 2: Industry Trends - The recent IPO applications reflect a clear trend towards specialization in specific therapeutic areas, with oncology remaining a core battlefield. Companies like New Bridge Bio focus on precision immuno-oncology drugs targeting solid tumors, while others like Lupan Pharma are developing oral drug platforms for cancer and autoimmune diseases [7][8]. - The financial health of biopharmaceutical companies shows marked differentiation, with many unprofitable biotech firms facing ongoing financial pressure. For instance, New Bridge Bio reported cumulative losses of $239 million by mid-2025, despite a significant reduction in net losses due to one-time gains [8][9]. Group 3: Financial Performance - Companies with revenue are experiencing imbalances between scale and profitability. For example, Demy Pharma's revenue grew by 30.7% to 617.5 million CNY in 2024, but net losses surged from 4.7 million to 105.6 million CNY, primarily due to high sales expenses [9]. - Companies like Libang Pharma and Jiangxi Biopharmaceuticals are leveraging their unique market positions and product pipelines to navigate the competitive landscape, with Libang focusing on chronic kidney disease and Jiangxi capitalizing on its long-standing expertise in antitoxins [10][11]. Group 4: Risks and Challenges - Supply chain and customer structure risks are prominent in some companies, with Demy Pharma's top five customers contributing 61.3% of revenue and top suppliers accounting for 81.6% of purchases, indicating vulnerability to supply disruptions [11]. - The article emphasizes that successful IPOs are just the beginning, as valuation and market competition will pose significant challenges for these biopharmaceutical firms. The need for continuous R&D investment is critical for maintaining competitive advantage [12][13]. Group 5: Strategic Insights - For traditional pharmaceutical companies, demonstrating sustainable growth is essential. Jiangxi Biopharmaceuticals, for instance, must balance its established product lines with innovative developments to enhance its valuation [14]. - The article suggests that optimizing operational efficiency is more crucial than merely expanding scale for already commercialized companies. Demy Pharma's case illustrates the need for a balance between marketing expenses and R&D investments to sustain growth [14][15].

关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于投资者可于 2025 年 11 月 07 日（星期五）至 11 月 13 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集" 栏目或通过公司邮箱 ir@hinovapharma.com 进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 海创药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入 地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 14 日（星期五）14:00-15:000 举行 2025 年第三季度业绩说 明会，就投资者关心的问题进行交流。 证券代码：688302 证券简称：海创药业 公告编号：2025-049 海创药业股份有限公司 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年第三季度的经营成果及财务指标的具体 ...